Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main objective of this project is to assess the effects of a novel and supervised exercise intervention in overweight pregnant and their newborn.
Methods/Design: The present study is a Randomized Controlled Trial. Sixty overweight pregnant interested in participate in the intervention program will be randomly assigned to either exercise (3 sessions/week), or to usual care (control) group (30 pregnant per group). The primary outcome measures are maternal weight gain, and maternal and neonatal glycaemic profile. Secondary outcomes measure are: i) body composition; ii) dietary patterns; iii) physical fitness; iv) objectively measured physical activity and sedentary behaviour; v) sleep quality; vi) mental health, quality of life and positive health; vii) haematology and biochemical analysis; viii) oxidative stress; ix) pro- and anti-inflammatory markers; x) bone health biomarkers; xi) adiposity-related proteins expression. The data will be analysed on an intention-to-treat basis and per protocol.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Gestafitos | Experimental | This is a longitudinal study developed, which is the continuation of the GESTAtion and FITness (GESTAFIT) Project. The main purpose is to evaluate the influence of a concurrent physical exercise program during pregnancy (developed under the GESTAFIT project) on the body composition, physical fitness, brain structure, and motor, cognitive, and language development of the offspring at four years of age. |
|
| Placentraining | Experimental | This is a retrospective study which purpose is to analyse the status of placentas of women participating in the GESTAFIT project, in which a concurrent physical exercise programme was developed. This rigorous design will allow us to test our central hypothesis that exercise during pregnancy will produce greater improvements in placental metabolic pathways associated with pregnancy complications, and is associated with better pregnancy and newborn outcomes. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Exercise intervention | Other | The exercise intervention will be performed in two groups so that each group will have 12-13 participants.The groups will train 3 days/week (60min per session) from the 16th week of gestation until delivery. The exercise intervention group will go through different phases of training: a) Learning phase: which will involve the intervention plan, the goals we want to work, and how we will perform it; b) Movement Learning phase: theoretical and practical sessions with the explanation of movements and ergonomic basic patterns; and c) Physical Fitness Training phase: with training sessions aimed at improving fitness and weight loss, and training sessions focused on a correct pelvic mobilization for the delivery.The intensity will be adapted during the exercise program based on the week of gestation and each pregnant heart rate. The sessions will consist of a mixed work, composed of circuits where both muscular and cardiovascular conditioning will be implemented. |
| Measure | Description | Time Frame |
|---|---|---|
| Insulin sensitivity derived from the homeostatic model assessment for insulin resistance (HOMA-IR) | Insulin sensitivity will be derived from the homeostatic model assessment for insulin resistance (HOMA-IR), which will be calculated using the formula [fasting insulin (μIU/mL) x fasting glucose (mg/dL)]/405. | 34th week of gestation |
| Maternal weight gain (kg) | Maternal weight gain will be defined as the weight change from baseline measurement to the last measurement | 34th week of gestation |
| Neonatal insuline-glucose index | Neonatal insulin sensitivity will be assessed through the ratio glucose/insulin. | At delivery in cord blood samples |
| Measure | Description | Time Frame |
|---|---|---|
| Systolic and diastolic blood pressure (mmHg) | Systolic and diastolic blood pressure (mmHg) will be measured after 5 minutes of rest, on 2 separate occasions (with 2 minutes between trials), with the person seated (Omron Health Care Europe B.V. Hoolddorp). The lowest value of the two trials will be selected for the analysis. | at the 16th and 34th week of gestation |
Not provided
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pilar Cabello-Turmo | Granada | Granada | 18071 | Spain |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37525559 | Derived | Marin-Jimenez N, Baena-Garcia L, Coll-Risco I, Flor-Alemany M, Castro-Pinero J, Aparicio VA. Influence of a Concurrent Exercise Training Program on Health-Related Quality of Life During Advanced Pregnancy: The GESTAFIT Project. Sports Health. 2024 Jul-Aug;16(4):518-526. doi: 10.1177/19417381231189730. Epub 2023 Jul 31. | |
| 35989614 |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009043 | Motor Activity |
| D007249 | Inflammation |
| ID | Term |
|---|---|
| D001519 | Behavior |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D035061 | Control Groups |
| ID | Term |
|---|---|
| D015340 | Epidemiologic Research Design |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D012107 | Research Design |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Control group | Other | Usual care, not exercise. |
|
| Resting heart rate (bpm) | Resting heart rate (bpm), will be measured after 5 minutes of rest, on 2 separate occasions (with 2 minutes between trials), with the person seated (Omron Health Care Europe B.V. Hoolddorp). The lowest value of the two trials will be selected for the analysis. | at the 16th and 34th week of gestation |
| The Mediterranean Diet Score | The Mediterranean Diet Score in a version adapted to the specific needs during pregnancy for Fe, Ca and folic acid will be used to assess the adherence to the traditional Mediterranean dietary pattern. | at the 16th and 34th week of gestation |
| Cardiorespiratory fitness (Vo2max) | The modified Bruce protocol will be performed to estimate maximal oxygen uptake (VO2max), and will be used as measure of cardiorespiratory fitness. | at the 16th and 34th week of gestation |
| Cardiorespiratory fitness (meters in the 6-min walk test) | We perform the 6-minute walk test, which measures the maximum distance (in meters) each participant can walk in 6 minutes along a 45.7 m rectangular course. | at the 16th and 34th week of gestation |
| Muscle strength (kg) | The handgrip strength test will be used as measure of strength | at the 16th and 34th week of gestation |
| Flexibility (cm) | The back-scratch test will be used as measure of flexibility | at the 16th and 34th week of gestation |
| Physical activity and sedentary behaviour (in minutes) | Accelerometry will be used to objectively assess physical activity and sedentary time. Women will be asked to wear a tri-axial accelerometer (ActiSleep+, Pensacola, Florida, United States) for 9 consecutive days, starting the same day they receive the monitor (e.g. participants who receive the accelerometer on Monday, will carry the device until Tuesday of the next week). Participants will be instructed to wear the accelerometer during the whole day (24 hours) on their wrist attached by an elastic belt. Time (in minutes) engaged in light, moderate, and moderate-vigorous intensity PA and sedentary time will be calculated. This accelerometer has been previously used in pregnancy with similar methodology as described in the present protocol. | at the 16th, 24th and 34th week of gestation |
| Sleep behaviours (through accelerometry) | Behaviours related to sleep, such as sleep onset, sleep latency, total sleep time, number and duration of awakenings and sleep efficiency will be objectively calculated by using a triaxial accelerometer (ActiSleep+, Pensacola, Florida, United States). The data analysis of such ActiSleep accelerometry data will be carried out through its specific software (Actilife). | at the 16th, 24th and 34th week of gestation |
| Pittsburgh Sleep Quality Index | It will be used to assess sleep quality and disturbances over a l-month time interval. | at the 16th, 24th and 34th week of gestation |
| Insomnia Symptoms Questionnaire | The presence of symptoms of insomnia will be measured with the Insomnia Symptoms Questionnaire, validated in pregnant women. | at the 16th, 24th and 34th week of gestation |
| Quality of life (Short-Form Health Survey 36) | We will use the Short-Form Health Survey 36, for assessing health-related quality of life. | at the 16th and 34th week of gestation |
| Epidemiological Studies-Depression Scale questionnaire | The pregnant antenatal depression levels will be assessed by the Center for Epidemiological Studies-Depression Scale questionnaire, which is validated and widely employed in pregnancy. | at the 16th and 34th week of gestation |
| State Trait Anxiety Index. | Anxiety levels will be assessed with the State Trait Anxiety Index. | at the 16th and 34th week of gestation |
| The Detention of Restless Legs Syndrome questionnaire | The "Restless Legs Syndrome" largely determines the quality of life for many pregnant and is related to their levels of depression and sleep quality. The Spanish version of the Detention of Restless Legs Syndrome questionnaire will be employed to assess the presence and severity of this syndrome . | at the 16th and 34th week of gestation |
| Oswestry Disability Index score | Low-back pain will be assessed with the Spanish version of the Oswestry Disability Index score | at the 16th and 34th week of gestation |
| Pain Visual Analogue Scale | Low-back pain intensity will be also assessed with the Pain Visual Analogue Scale | at the 16th and 34th week of gestation |
| 6-item Female Sexual Function Index | The 6-item Female Sexual Function Index will be used to assess sex function. This instrument is composed of six questions: desire, arousal, lubrication, orgasm, satisfaction and pain. Each question can be scored from 0 to 5 and then summed up to provide a total score. | at the 16th and 34th week of gestation |
| Positive health | "Positive health" will be evaluated through the following questionnaires:
| at the 16th and 34th week of gestation |
| Haematology | Erythrocyte count, haematocrit, haemoglobin, platelets, leukocytes and erythrocyte mean corpuscular volume will be quantified by Coulter (Brand). | at 34th week of gestation and at delivery |
| Lipid profile (in mother and cord blood) | Plasma total, high-density lipoprotein and low-density lipoprotein cholesterol and triglycerides (all in mg/dL) will be assessed using an autoanalyzer (Hitachi-Roche p800, F. Hoffmann-La Roche Ltd. Switzerland) | at 34th week of gestation and at delivery |
| Glycaemic profile (in mother and cord blood) | Plasma glucose, insulin and glycosylated haemoglobinwill be assessed using an autoanalyzer (Hitachi-Roche p800, F. Hoffmann-La Roche Ltd. Switzerland) | at 34th week of gestation and at delivery |
| Total plasma antioxidant capacity (in mother and cord blood) | It will be measured by using commercial kit (spectrophotometry). | at 34th week of gestation and at delivery |
| Plasma liposoluble antioxidants (in mother and cord blood) | Plasma vitamin E, retinol, carotene, coenzyme Q10 and coenzyme Q9 will be measured through mass spectrometry | at 34th week of gestation and at delivery |
| Antioxidant enzymes activity (in mother and cord blood) | Eritrocite membrane catalase, glutathione peroxidase and superoxide dismutase enzymes will be by measured by spectrophotometry. | at 34th week of gestation and at delivery |
| Carbonyl proteins (in mother and cord blood) | Measurement of carbonyl proteins will be done by using commercial kit (spectrophotometry). | at 34th week of gestation and at delivery |
| Oxidative damage to lipids (in mother and cord blood) | Measurement of 4-hydroxynonenal and isoprostanes in urine and plasma and hydroperoxides in plasma and erythrocyte membrane by using commercial kits (spectrophotometry and ELISA) | at 34th week of gestation and at delivery |
| Oxidative damage to DNA (in mother and cord blood) | measurement of 8-hydroxyguanosine in urine and plasma by commercial kits (ELISA). | at 34th week of gestation and at delivery |
| Pro- and anti-inflammatory signal (in mother and cord blood) | Some maternal and umbilical cord plasma pro-inflammatory and anti-inflammatory cytokines (IL-1β, IL-2, IL-6, IL-8, IL-10, IFN-γ and TNF-α, IL-1ra and TNF Srii α), some adipokines (adiponectin, adipsin, resistin, PAI-active, insulin and leptin) and myokines (irisin) will be measured by the employment of Luminex xMAP technology. | at 34th week of gestation and at delivery |
| Bone biomarkers (in mother and cord blood) | Various relevant biomarkers related to bone metabolism (ACTH, DKK-1, FGF-23, Osteocalcin, OPN-Osteopontin, Osteoprotegerin, PTH and SOST) will be measured with Luminex xMAP technology. | at 34th week of gestation and at delivery |
| Adiposity-related proteins expression (in mother and cord blood) | Glucocorticoid receptor; peroxisome proliferation activated receptor (PPAR); the beta-11 hydroxysteroid dehydrogenase type I (11βHSD1), and beta-11 hydroxysteroid dehydrogenase type II (11βHSD2) will be assessed in maternal and umbilical cord blood and in oral mucosa from the mother and newborn. Moreover, 4 genes highly involved in foetal and postnatal development of adipose tissue have been selected; two are receptors: the Glucocorticoid receptor and the PPAR-γ, and two are metabolic enzymes: beta-11 hydroxysteroid dehydrogenase type I or 11βHSD1, and 11 beta-hydroxysteroid dehydrogenase type II or 11βHSD2. Of great importance are PPAR-γ1 and PPAR-γ2, which are generated from the same gene by alternative promoter usage and mRNA. We will measure such proteins as well as paraoxonase/arylesterase 1 (PON1) concentrations in maternal and umbilical cord plasma by Polymerase Chain Reaction and Western Blot techniques. | At delivery |
| Anthropometry and Body Composition of the Mother and Child (Gestafitos) | The height of the mother and child will be recorded using a scale (Seca 22, Hamburg). A comprehensive analysis of body composition will be carried out for both the mother and child (DXA, Hologic Discovery QDR, Nasdaq). We will also record weight (Inbody R20, Biospace, Korea) as well as waist and neck circumference in both the mother and child. | 4 ± 1 years after birth |
| Blood Pressure and Resting Heart Rate of the Mother and Child (Gestafitos) | Systolic and diastolic blood pressure, along with heart rate, will be measured three times after 5 minutes of rest (Omron Hoolddorp) in both mother and child. | 4 ± 1 years after birth |
| Nutritional Status of the Mother and Child (Gestafitos) | A food frequency questionnaire and a Mediterranean Diet Adherence questionnaire will be administered. The use of nutritional supplements will also be recorded. | 4 ± 1 years after birth |
| Physical Activity, Sedentary Behavior, and Sleep Quality of the Mother and Child | We will assess physical activity, sedentary behavior, and sleep-related behaviors (latency, efficiency, etc.) using accelerometers (ActigraphGT3X+, Pensacola, Florida, USA) worn on the wrist for nine consecutive days. Acceleration changes will be recorded in 5-second epochs for children and 60-second epochs for mothers. Data will be collected on total volume and intensity of activity (mean physical activity intensity), energy expenditure, and the number of minutes per day spent at various intensities: low (sedentary), light, moderate, vigorous, and moderate-to-vigorous. Sleep quality will also be recorded using the specific Actisleep software. | 4 ± 1 years after birth |
| Health-Related Physical Fitness of the Child: PREFIT Battery | Muscular strength, cardiorespiratory fitness, balance, speed, and motor coordination-agility will be assessed using the following PREFIT battery tests: 20m shuttle run test, handgrip dynamometry, standing long jump test, one-leg balance test, and 4x10m shuttle run test, respectively. The PREFIT battery is a feasible, reliable, maximal, and valid tool to assess physical fitness in preschool-aged children. | 4 ± 1 years after birth |
| Brain Structure, Cerebral Blood Flow, and Brain Function via Structural and Functional Magnetic Resonance Imaging (Gestafitos) | MRI will be conducted at the Brain, Mind and Behavior Research Center (CIMCYC) at the University of Granada. Dr. Irene Esteban-Cornejo, a team member, has coordinated the neuroimaging area of previously funded studies (e.g., the ACTIVEBRAINS project, a randomized controlled trial assessing the effect of exercise on the brain in children). She has completed two research stays at the Monash Institute of Cognitive and Clinical Neurosciences in Australia, holds a Master's degree in advanced MRI analysis, and is the first author of the first two brain articles from the ACTIVEBRAINS project, both published in the prestigious journal Neuroimage. Dr. Esteban-Cornejo has also worked with leading experts in exercise and brain health (Erickson KI, Kramer AF, and Hillman CH) at Northeastern University and the University of Pittsburgh. Dr. Erickson and neuroscientist Marina López-Solà are also part of the current project team. | 4 ± 1 years after birth |
| Cognition (Gestafitos) | Three key aspects of executive function will be assessed:
| 4 ± 1 years after birth |
| Academic Performance (Gestafitos) |
Other Motor, Cognitive, and Language Development Scales:
| 4 ± 1 years after birth |
| Genetic and Epigenetic Analyses (Gestafitos) | Buccal mucosa samples will be collected from children to analyze the expression of the FTO gene polymorphism rs9939609 and MC4R gene polymorphism rs17782313. DNA will be extracted from saliva using Whatmann® paper supports and organic extraction methods optimized for quality and quantity. Samples will be quantified using a NanoDrop 2000 spectrophotometer (ThermoScientific) and normalized to ~5 ng/µL before being genotyped with TaqMan probes (Applied Biosystems) on a RealTime ABI PRISM® 7900 HT. Unsuccessful samples will be amplified and sequenced using specific primers and analyzed with the 3130 HID Genetic Analyzer (Applied Biosystem). DNA and RNA will be extracted using the QIAamp DNA Mini Kit and DNeasy Blood & Tissue Kit (Qiagen), and processed with the Qiacube robot. | 4 ± 1 years after birth |
| Oxidative stress and antioxidant defence (Placentraining) | The content in placenta of fat-soluble antioxidants (tocopherol, coenzyme Q10 and Q9 and retinol) will be analysed by HPLC, and nitric oxide and the total antioxidant capacity by the ABTS method.
| after placental expulsion following birth |
| Expression of markers of biogenesis, autophagy, mitochondrial fusion-fission processes (Placentraining) | Changes inmitochondrial dynamics and their quality control are a key aspect to explain the observed findings. Therefore, using Western-blotting or RT-PCR, the mitochondrial processes of fission (Drp1, Fis1 and OPA1), fusion (Mfn1 and Mfn2), biogenesis (PGC1alpha, Tfam, Sirt1, Nrf1, Nrf2) and autophagy (PARKIN2, PINK1, Beclin-1, ATG8, ATG5, ATG12, VDAC1). | after placental expulsion following birth |
| Trace and ultra-trace minerals (Placentraining) | The determination of total content of these essential (Ca, Mg, Mn, Fe, Cu, Zn, Se) or toxic elements (Hg, V, Cr, As, Cd, Pb, Ni) in placenta samples will be performed by an ICP-MS instrument (Agilent 7500, Agilent Technologies, Tokyo, Japan) fitted with a Meinhard type nebulizer (Glass Expansion, Romainmotier) and equipped with a He collision cell. | after placental expulsion following birth |
| Genomic and methylation (Placentraining) | Samples will be processed as it is previously described in the "Genetic analyses section". Genomic and Methylation will be developed by pyrosequencing method. This will be developed for detection of FTO and MC4R genes. Genomic DNA from placentas will be isolated using DNeasy Blood&Tissue Kit following the recommended protocol (Qiagen N.V, Hi.GE). After checking the quality and quantity of the DNA, the promoters of the FTO and MC4R genes will be amplified by means of predesigned PyroMark CpG Assays. Region amplification using these primers will allow us to directly quantify the methylation status of the CGs within the region. First, we will amplify FTO and MC4R regions of interest by PCR using the PyroMark PCR Kit (QIAGEN N.V, Hi.GE), which enables labelling CG nucleotides susceptible of being methylated. Reaction products (one per sample and gene) will be purified and used for the sequencing reaction. | after placental expulsion following birth |
| Candidate gene expression and Small RNA analysis (Placentraining) | For a better understanding of the metabolic pathways involved, we will carry out the study of candidate genes, as well as the determination of miRNAs that will allow us to establish a genotype-expression-environment relationship (with Small RNA Sequencing analysis). For mRNA and miRNA analysis, placental RNA will be obtained through the kit "RNeasy Mini" (Qiagen) following the manufacturer instructions. RNA integrity will be analyzed by a "RNA 6000 Nano chip" (Agilent) using a Bionalalyzer 2100 (Agilent) and the concentration will be calculated by NanoDrop 2000 (ThermoFisher Scientific). Predesigned TaqMan Gene Expression assays (ThermoFisher Scientific) will be used to study the expression of candidate genes: IL6, CXCL8, TNF-alpha, CSF3, BDNF; FTO, MC4R and KL klotho (KL). | after placental expulsion following birth |
| Targeted and untargeted metabolomics and lipidomics analyses | Targeted metabolomics analyses will be performed using liquid chromatography coupled to mass spectrometry. Lipid species extraction will be extracted from plasma samples with MTBE. Ten μL of the extracted sample will be applied onto UPLC 1290 (Agilent Technologies, Barcelona, Spain) equipped with a reversed-phase column coupled to QTOF mass spectrometer model 6545 (Agilent Technologies, Barcelona, Spain). Data will be collected in positive and negative electrospray modes. MassHunter (Agilent Technologies, Barcelona, Spain) and R software will be used to collect, extract, align, filter and normalize the data using quality controls. Untargeted metabolomics analyses will be performed using liquid chromatography coupled to mass spectrometry. Metabolite extraction will be extracted from plasma samples with methanol. | after placental expulsion following birth |
| Toxics (Placentraining) | Concentrations of free bioactive phenols will be determined by multiclass ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). The following phenols will be assessed: bisphenol A; parabens: methylparaben, ethylparaben, propylparaben, butylparaben; benzofenonas (BzP): BzP-1, BzP-2, BzP-3, BzP-6, BzP-8, 4-hydroxy-BzP. Concentrations of perfluoroalkyl substances in placenta will be assessed by coupling salt assisted liquid-liquid extraction with dispersive liquid-liquid microextraction and UHPLC-MS/MS. The following perfluoroalkyl substances will be measured: PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnA, PFDoA, PFTrA, PFHxS and PFOS. | after placental expulsion following birth |
| Inflammatory, anti-inflammatory, vasculogenesis and angiogenesis markers (Placentraining) | We will use Luminex xMAP technology (Millipore, Darmstadt, Germany) kits to assess placenta Fractalkine, IL-1α, IL1β, IL-RA, IL-2, IL-6, IL-8, IL-10, IFN-γ, TNF-α, TNF-β, Brain-derived neurotrophic factor, Epidermal growth factor, Fibroblast growth factor 2, Granulocyte-colony stimulating factor, Granulocyte-macrophage colony-stimulating factor, Platelet-derived growth factor-AA, Monocyte chemoattractant protein-1, Vascular endothelial growth factor. For these determination we will use Human Sepsis Magnetic Bead Panel 3 Multiplex Assay (cat. No. HTH17MAG-14K). | after placental expulsion following birth |
| Aparicio VA, Baena-Garcia L, Flor-Alemany M, Martinez-Gonzalez LJ, Varela-Lopez A, Sanchez C, Quiles JL. Differences in maternal and neonatal cardiometabolic markers and placenta status by foetal sex. The GESTAFIT project. Womens Health (Lond). 2022 Jan-Dec;18:17455057221117976. doi: 10.1177/17455057221117976. |
| 32069319 | Derived | Baena-Garcia L, Coll-Risco I, Ocon-Hernandez O, Romero-Gallardo L, Acosta-Manzano P, May L, Aparicio VA. Association of objectively measured physical fitness during pregnancy with maternal and neonatal outcomes. The GESTAFIT Project. PLoS One. 2020 Feb 18;15(2):e0229079. doi: 10.1371/journal.pone.0229079. eCollection 2020. |
| 29601268 | Derived | Aparicio VA, Ocon O, Diaz-Castro J, Acosta-Manzano P, Coll-Risco I, Borges-Cosic M, Romero-Gallardo L, Moreno-Fernandez J, Ochoa-Herrera JJ. Influence of a Concurrent Exercise Training Program During Pregnancy on Colostrum and Mature Human Milk Inflammatory Markers: Findings From the GESTAFIT Project. J Hum Lact. 2018 Nov;34(4):789-798. doi: 10.1177/0890334418759261. Epub 2018 Mar 30. |
| 27680325 | Derived | Aparicio VA, Ocon O, Padilla-Vinuesa C, Soriano-Maldonado A, Romero-Gallardo L, Borges-Cosic M, Coll-Risco I, Ruiz-Cabello P, Acosta-Manzano P, Estevez-Lopez F, Alvarez-Gallardo IC, Delgado-Fernandez M, Ruiz JR, Van Poppel MN, Ochoa-Herrera JJ. Effects of supervised aerobic and strength training in overweight and grade I obese pregnant women on maternal and foetal health markers: the GESTAFIT randomized controlled trial. BMC Pregnancy Childbirth. 2016 Sep 29;16(1):290. doi: 10.1186/s12884-016-1081-y. |
| D008722 | Methods |